Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- anticholesteremic agents
- heptanoic acids
- myocardial infarction
- hydroxymethylglutaryl-CoA reductase inhibitors
Q In patients with an acute coronary syndrome (ACS), is standard dose pravastatin non-inferior to high dose atorvastatin for reducing death or major cardiovascular (CV) events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆
randomised, placebo controlled trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] trial).
blinded (clinicians and patients).*
Follow up period:
mean 24 months.
349 sites in 8 countries.
4162 stable patients (mean age 58 y, 78% men) who were hospitalised for an ACS in the previous 10 days, were enrolled after a percutaneous revascularisation procedure (if planned), and had a total cholesterol concentration ⩽240 mg/dl (6.21 mmol/l) taken within the first 24 hours, or <6 months …